The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,300.00
Bid: 12,298.00
Ask: 12,302.00
Change: -64.00 (-0.52%)
Spread: 4.00 (0.033%)
Open: 12,358.00
High: 12,376.00
Low: 12,276.00
Prev. Close: 12,364.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

29 Apr 2020 16:00

RNS Number : 3749L
AstraZeneca PLC
29 April 2020
 

29 April 2020 16:00 BST

 

Results of Annual General Meeting held on 29 April 2020

 

AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 10 - 13 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.

 

RESOLUTION

VOTES FOR

% OF VOTES CAST

VOTES AGAINST

% OF VOTES CAST

VOTES CAST IN TOTAL

TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL

VOTES WITHHELD

1

To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2019

 

1,061,180,101

99.92

872,215

0.08

1,062,052,316

80.93%

7,121,452

2

To confirm dividends

 

1,058,995,786

99.10

9,598,531

0.90

1,068,594,317

81.43%

579,469

3

To reappoint PricewaterhouseCoopers LLP as Auditor

 

1,068,300,235

99.97

312,449

0.03

1,068,612,684

81.43%

560,776

4

To authorise the Directors to agree the remuneration of the Auditor

 

1,067,398,628

99.90

1,086,858

0.10

1,068,485,486

81.42%

687,961

5a

To re-elect Leif Johansson as a Director

 

1,065,113,167

99.69

3,276,071

0.31

1,068,389,238

81.42%

784,805

5b

To re-elect Pascal Soriot as a Director

 

1,067,248,723

99.90

1,033,124

0.10

1,068,281,847

81.41%

892,364

5c

To re-elect Marc Dunoyer as a Director

 

1,060,164,242

99.25

8,056,265

0.75

1,068,220,507

81.40%

952,979

5d

To re-elect Geneviève Berger as a Director

 

882,846,920

83.06

179,994,848

16.94

1,062,841,768

80.99%

6,331,650

5e

To re-elect Philip Broadley as a Director

 

1,066,048,992

99.79

2,190,705

0.21

1,068,239,697

81.41%

933,713

5f

To re-elect Graham Chipchase as a Director

 

1,062,682,507

99.48

5,520,936

0.52

1,068,203,443

81.40%

969,967

5g

To elect Michel Demaré as a Director

 

1,066,252,259

99.82

1,969,593

0.18

1,068,221,852

81.40%

951,558

5h

To re-elect Deborah DiSanzo as a Director

 

1,067,836,362

99.97

351,091

0.03

1,068,187,453

81.40%

985,957

5i

To re-elect Sheri McCoy as a Director

 

1,064,329,862

99.64

3,890,368

0.36

1,068,220,230

81.40%

951,792

5j

To re-elect Tony Mok as a Director

1,067,117,370

99.90

1,066,669

0.10

1,068,184,039

81.40%

989,371

5k

To re-elect Nazneen Rahman as a Director

 

1,067,376,963

99.92

821,467

0.08

1,068,198,430

81.40%

973,592

5l

To re-elect Marcus Wallenberg as a Director

 

955,082,665

89.42

113,060,725

10.58

1,068,143,390

81.40%

1,030,019

6

To approve the Annual Report on Remuneration for the year ended 31 December 2019

 

1,032,308,145

96.65

35,747,783

3.35

1,068,055,928

81.39%

1,118,038

7

To approve the Directors' Remuneration Policy

 

972,774,742

94.71

54,292,376

5.29

1,027,067,118

78.27%

42,106,679

8

To authorise limited political donations

 

1,038,907,152

97.75

23,872,400

2.25

1,062,779,552

80.99%

6,394,668

9

To authorise the Directors to allot shares

 

910,654,650

85.26

157,472,093

14.74

1,068,126,743

81.40%

1,046,979

10

To authorise the Directors to disapply pre-emption rights

 

1,058,066,972

99.23

8,200,338

0.77

1,066,267,310

81.26%

2,906,339

11

To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments

 

1,054,711,677

98.92

11,513,414

1.08

1,066,225,091

81.25%

2,948,557

12

To authorise the Company to purchase its own shares

 

1,051,131,060

98.41

16,950,800

1.59

1,068,081,860

81.39%

1,091,896

13

To reduce the notice period for general meetings

 

998,062,805

93.44

70,101,553

6.56

1,068,164,358

81.40%

1,008,865

14

To approve the 2020 Performance Share Plan

1,010,149,491

95.66

45,877,396

4.34

1,056,026,887

80.48%

13,147,356

 

Issued capital

As at 27 April 2020, the number of issued shares of the Company was 1,312,240,429 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

 

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGPPURCCUPUGCB
Date   Source Headline
1st May 20203:00 pmRNSTotal Voting Rights
29th Apr 20204:00 pmRNSResult of AGM
29th Apr 20207:00 amRNSAZN: first-quarter 2020 results
24th Apr 20207:00 amRNSLynparza shows overall survival in prostate cancer
17th Apr 202011:00 amRNSChanges to arrangements for AGM
14th Apr 20207:00 amRNSKoselugo (selumetinib) approved in the US for NF1
14th Apr 20207:00 amRNSTagrisso adjuvant trial overwhelmingly positive
2nd Apr 20207:00 amRNSAstraZeneca divestment of Movantik completed
1st Apr 20203:00 pmRNSTotal Voting Rights
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
30th Mar 20207:01 amRNSImfinzi approved in US for small cell lung cancer
30th Mar 20207:00 amRNSFarxiga CKD trial early stop for positive efficacy
26th Mar 20207:00 amRNSLokelma approved in Japan for hyperkalaemia
26th Mar 20207:00 amRNSDirector/PDMR Shareholding
24th Mar 20204:41 pmRNSSecond Price Monitoring Extn
24th Mar 20204:36 pmRNSPrice Monitoring Extension
24th Mar 202012:02 pmRNSPrice Monitoring Extension
23rd Mar 20204:40 pmRNSSecond Price Monitoring Extn
23rd Mar 20204:36 pmRNSPrice Monitoring Extension
23rd Mar 202012:08 pmRNSSecond Price Monitoring Extn
23rd Mar 202012:03 pmRNSPrice Monitoring Extension
20th Mar 202010:20 amRNSSecond Price Monitoring Extn
20th Mar 202010:15 amRNSPrice Monitoring Extension
20th Mar 20207:00 amRNSDirector/PDMR Shareholding
19th Mar 20207:00 amRNSLynparza granted orphan drug designation in Japan
17th Mar 20207:00 amRNSImfinzi confirmed overall survival in CASPIAN
13th Mar 20204:35 pmRNSPrice Monitoring Extension
12th Mar 202011:00 amRNSNotice of AGM
12th Mar 20207:00 amRNSUpdate on Phase III GY004 trial for cediranib
10th Mar 20207:00 amRNSDirector/PDMR Shareholding
6th Mar 20207:00 amRNSUpdate on Phase III DANUBE trial in bladder cancer
4th Mar 20207:00 amRNSFiling of Form 20-F with SEC
3rd Mar 202011:00 amRNSAnnual Financial Report
2nd Mar 20203:00 pmRNSTotal Voting Rights
2nd Mar 20207:00 amRNSDivestment of hypertension medicines completed
27th Feb 20207:00 amRNSDirector/PDMR Shareholding
25th Feb 20207:00 amRNSAstraZeneca divests global rights to Movantik
19th Feb 20207:00 amRNSDirector/PDMR Shareholding
14th Feb 20207:00 amRNSAZN: Full-year and Q4 2019 results
3rd Feb 20203:00 pmRNSTotal Voting Rights
27th Jan 20207:00 amRNSEnhertu Phase II trial met primary endpoint
27th Jan 20207:00 amRNSBrilinta met primary endpoint in stroke trial
27th Jan 20207:00 amRNSAstraZeneca divests hypertension medicines
27th Jan 20207:00 amRNSAstraZeneca to recover brazikumab (MEDI2070)
20th Jan 20207:00 amRNSFDA grants Lynparza Priority Review for PROfound
20th Jan 20207:00 amRNSImfinzi, tremelimumab granted ODD in liver cancer
13th Jan 20207:01 amRNSLynparza granted FDA Priority Review for PAOLA-1
13th Jan 20207:00 amRNSUpdate on Epanova Phase III STRENGTH trial
6th Jan 20207:01 amRNSFarxiga granted FDA heart failure Priority Review
6th Jan 20207:00 amRNSLokelma approved in China for hyperkalaemia

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.